LETTERS TO THE EDITOR
ADVANCE praise
George A. Diamond, MD, FACC
2408 Wild Oak Drive Los Angeles, CA 90068
(Email: gadiamond{at}pol.net).
Sometimes an artfully crafted quasi-acronym can help distinguish one otherwise indistinguishable clinical advance from another (1–3). The infectiousness of this engaging wOrdPlay is evidenced by a recent report describing the role of Tirofiban for prevention of iscHEmIc complicatioNS among high-risk pAtieNts undergoIng coronary angioplasTY (4)—a distinguished advance indeed!
 |
References
|
|---|
1. The ADVANCE Investigators Rationale and design of the ADVANCE study: a randomized trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitusAction in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation. J Hypertens Suppl 2001;19 Suppl 4:S21-8.
2. Serruys PW, Foley DP, Suttorp MJ, et al. A randomized comparison of the value of additional stenting after optimal balloon angioplasty for long coronary lesions: final results of the additional value of NIR stents for treatment of long coronary lesions (ADVANCE) study J Am Coll Cardiol 2002;39:393-399.[Abstract/Free Full Text]
3. Russell SD, Selaru P, Pyne DA, et al. Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial Am Heart J 2003;145:179-186.[CrossRef][Web of Science][Medline]
4. Valgimigli M, Percoco GF, Barbieri D, et al. The additive value of tirofiban administered with the high dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty (ADVANCE) trial J Am Coll Cardiol 2004;44:14-19.[Abstract/Free Full Text]
Related Article
-
Reply
- Marco Valgimigli and Patrick W. Serruys
J. Am. Coll. Cardiol. 2005 45: 469.
[Full Text]
[PDF]
|
Top
References